Statin use and delayed onset of Huntington's disease

Autor: Peg Nopoulos, John Kamholz, Jordan L. Schultz, Annie Killoran
Rok vydání: 2018
Předmět:
Oncology
0301 basic medicine
Adult
Male
medicine.medical_specialty
Statin
medicine.drug_class
Article
genetics [Huntington Disease]
03 medical and health sciences
Text mining
0302 clinical medicine
Huntington's disease
Trinucleotide Repeats
Internal medicine
Medicine
Humans
ddc:610
Age of Onset
Propensity Score
Survival analysis
Aged
Proportional Hazards Models
Retrospective Studies
Huntingtin Protein
Movement Disorders
business.industry
Proportional hazards model
Hazard ratio
Delayed onset
Retrospective cohort study
Statin treatment
Middle Aged
medicine.disease
030104 developmental biology
Huntington Disease
Neurology
Propensity score matching
Disease Progression
Female
Neurology (clinical)
Age of onset
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
030217 neurology & neurosurgery
Zdroj: Movement disorders 34(5), 762-763 (2019). doi:10.1002/mds.27680
Mov Disord
ISSN: 1531-8257
DOI: 10.1002/mds.27680
Popis: Background There is evidence to suggest that 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) may be beneficial in Huntington's disease (HD). Objective This study aimed to determine if statin use was associated with delayed motor diagnosis in participants with premotor HD. Methods Among premotor HD participants from the Enroll-HD database, statin users were propensity score matched with statin nonusers based on cytosine-adenine-guanine-age product score, cytosine-adenine-guanine repeat length, baseline age, sex, and region. A Cox regression survival analysis compared the annualized hazard ratio (HR) of receiving a motor diagnosis between the 2 groups. Results The annualized HR of progressing to an HD motor diagnosis was lower in the statin users (n = 89) when compared with the statin nonusers (n = 89; HR = 0.27 [95% CI 0.18-0.50], P Conclusions In patients with premotor HD, statin use was associated with a delayed motor diagnosis of HD. Further studies are warranted to investigate if statins would be an effective disease-modifying therapy for HD. © 2018 International Parkinson and Movement Disorder Society.
Databáze: OpenAIRE
Externí odkaz: